Solanezumab Phase 3 Study Data from Lilly is Now Available on AD Workbench
AD Data Initiative is connecting the dots for the more than 55 million people living with Alzheimer’s disease and related dementias. See how data sharing and global collaboration can power the end of this devastating disease.